[go: up one dir, main page]

ES2178459T3 - Fosfohalohidrinas, procedimiento de fabricacion y aplicaciones. - Google Patents

Fosfohalohidrinas, procedimiento de fabricacion y aplicaciones.

Info

Publication number
ES2178459T3
ES2178459T3 ES99940247T ES99940247T ES2178459T3 ES 2178459 T3 ES2178459 T3 ES 2178459T3 ES 99940247 T ES99940247 T ES 99940247T ES 99940247 T ES99940247 T ES 99940247T ES 2178459 T3 ES2178459 T3 ES 2178459T3
Authority
ES
Spain
Prior art keywords
phosfohalohidrins
applications
manufacturing procedure
chosen
fohalohydrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99940247T
Other languages
English (en)
Inventor
Christian Belmant
Jean-Jacques Fournie
Marc Bonneville
Marie-Alix Peyrat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of ES2178459T3 publication Critical patent/ES2178459T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/098—Esters of polyphosphoric acids or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

Compuestos que comprenden por lo menos un grupo fos fohalohidrina de fórmula: en la que X es un halógeno elegido entre I, Br, Cl, R1 es elegido entre x CH3 y x CH2xCH3, Cat+ es un catión orgánico o mineral, y n es un número entero comprendido entre 2 y 20.
ES99940247T 1998-09-01 1999-08-27 Fosfohalohidrinas, procedimiento de fabricacion y aplicaciones. Expired - Lifetime ES2178459T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9810913A FR2782721B1 (fr) 1998-09-01 1998-09-01 Nouveaux composes phosphohalohydrines, procede de fabrication et applications

Publications (1)

Publication Number Publication Date
ES2178459T3 true ES2178459T3 (es) 2002-12-16

Family

ID=9530019

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99940247T Expired - Lifetime ES2178459T3 (es) 1998-09-01 1999-08-27 Fosfohalohidrinas, procedimiento de fabricacion y aplicaciones.

Country Status (12)

Country Link
US (4) US6660723B1 (es)
EP (1) EP1109817B1 (es)
JP (1) JP4603163B2 (es)
AT (1) ATE218576T1 (es)
AU (1) AU5426699A (es)
CA (1) CA2341574C (es)
DE (1) DE69901717T2 (es)
DK (1) DK1109817T3 (es)
ES (1) ES2178459T3 (es)
FR (1) FR2782721B1 (es)
PT (1) PT1109817E (es)
WO (1) WO2000012516A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2782722B1 (fr) * 1998-09-01 2001-01-12 Inst Nat Sante Rech Med Nouveaux composes phosphoepoxydes, procede de fabrication et applications
FR2782721B1 (fr) * 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Nouveaux composes phosphohalohydrines, procede de fabrication et applications
FR2791981B1 (fr) * 1999-04-06 2001-07-20 Inst Nat Sante Rech Med Composes inhibant selectivement les lymphocytes tgamma9delta2, et leurs applications
AU2002339423B2 (en) * 2001-07-20 2007-03-15 Bioagency Ag Organo-phosphorous compounds for activating gamma/delta T cells
US20050042751A1 (en) * 2001-10-31 2005-02-24 Michel Goldman Generation and use of new types of dendritic cells
FR2833266B1 (fr) 2001-12-11 2004-10-22 Mayoly Spindler Lab Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2
FR2836483B1 (fr) * 2002-02-22 2006-09-15 Innate Pharma Procedes de production de lymphocytes gamma delta t
GB0212666D0 (en) * 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
EP1426052B1 (en) * 2002-12-02 2009-09-02 Innate Pharma Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof
US20090186343A1 (en) * 2003-01-28 2009-07-23 Visigen Biotechnologies, Inc. Methods for preparing modified biomolecules, modified biomolecules and methods for using same
WO2005077411A2 (en) * 2004-02-10 2005-08-25 Innate Pharma Composition and method for the treatment of carcinoma
CA2564562A1 (en) 2004-04-26 2005-11-03 Innate Pharma Adjuvant composition and methods for its use
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
EA200702029A1 (ru) * 2005-03-22 2008-02-28 Иннейт Фарма НОВЫЙ КЛАСС АКТИВАТОРОВ γ;δ Т-КЛЕТОК И ИХ ПРИМЕНЕНИЕ
US20090087456A1 (en) * 2005-09-07 2009-04-02 James Edward Eyles Adjuvanted vaccine
WO2007039635A2 (en) * 2005-10-06 2007-04-12 Innate Pharma Phosphoantigen salts of organic bases and methods for their crystallization
EP1878440A1 (en) * 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
EP2083830A1 (en) 2006-11-17 2009-08-05 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
EP2123285A1 (en) * 2008-05-21 2009-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Intraocular Lenses Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
WO2014072446A1 (en) * 2012-11-08 2014-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for inducing il-2-free proliferation of gamma delta t cells
JP2022513328A (ja) 2018-09-27 2022-02-07 フォスフォガム， インコーポレイテッド 同種異系のガンマ／デルタｔ細胞の増殖および使用のための方法および組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06228004A (ja) * 1993-02-05 1994-08-16 Unitika Ltd 免疫抑制剤およびその製造方法
US5639653A (en) * 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
FR2715660A1 (fr) * 1994-01-28 1995-08-04 Centre Nat Rech Scient Composés organo-phosphorés activateurs des lymphocytes Tgammadelta, procédé pour préparer et/ou isoler et/ou caractériser ces composés, compositions et utilisations pharmaceutiques.
FR2782721B1 (fr) * 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Nouveaux composes phosphohalohydrines, procede de fabrication et applications
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT

Also Published As

Publication number Publication date
US20100068179A1 (en) 2010-03-18
DE69901717D1 (de) 2002-07-11
DE69901717T2 (de) 2003-02-13
JP4603163B2 (ja) 2010-12-22
US20060287281A1 (en) 2006-12-21
AU5426699A (en) 2000-03-21
FR2782721A1 (fr) 2000-03-03
DK1109817T3 (da) 2002-09-16
US20040087555A1 (en) 2004-05-06
CA2341574C (fr) 2011-02-08
JP2002523513A (ja) 2002-07-30
EP1109817B1 (fr) 2002-06-05
CA2341574A1 (fr) 2000-03-09
FR2782721B1 (fr) 2000-11-03
WO2000012516A1 (fr) 2000-03-09
ATE218576T1 (de) 2002-06-15
US7109183B2 (en) 2006-09-19
PT1109817E (pt) 2002-10-31
US6660723B1 (en) 2003-12-09
US7625879B2 (en) 2009-12-01
EP1109817A1 (fr) 2001-06-27

Similar Documents

Publication Publication Date Title
ES2178459T3 (es) Fosfohalohidrinas, procedimiento de fabricacion y aplicaciones.
BR9900177A (pt) Inibidores de metaloprotease.
BR0010242A (pt) Composições quìmicas que atraem artrópodes
BR0214230A (pt) Compostos e processos de fabricação de compostos
NL1002835A1 (nl) Synergistisch stabilisatormengsel.
ES2172864T3 (es) 2-metoxibenzofenonas fungicidas.
BR9708682B1 (pt) processo para a fabricação de tensoativos contendo grupos alquila de cadeia ramificada.
NO20003930L (no) Sammensetninger som inneholder organiske forbindelser
BR0108322A (pt) Caixa de câmbio
BR9909844B1 (pt) processo de preparação de compostos inibidores de cox-2.
TR199900853A3 (tr) Sübstitüe edilmis trisiklik bilesikler.
ITRM950392A0 (it) Composti organici.
BR0109542A (pt) Derivados de imidazopirina alquilados
ES2124893T3 (es) Nuevos complejos de inclusion de sales de nimesulida y de ciclodextrina.
ES2187184T3 (es) Fosfoepoxidos, procedimiento de fabricacion y aplicaciones.
EA200100854A1 (ru) Кальций-литические соединения
DK1073447T3 (da) N1-modificerede glycopeptider
BR9813731B1 (pt) lubrificante transportador antimicrobiano compatÍvel com bebida.
PT98268A (pt) Processo para a preparacao de indano-pirrolidino-carbamatos
DE69405379D1 (de) Universelles schloss fur pannensichere turen insbesondere fur aufzugsschachturen
MX9207179A (es) Procedimiento para tratar aguas residuales que contienen compuestos organicos de fosforo, especialmente arilfosfina sulfonada.
ES2117031T3 (es) Composiciones polimericas autoextinguentes.
SE9703413D0 (sv) Vehicle firewall
ES2189390T3 (es) Fungicidas.
UY24915A1 (es) Derivados de benzoxazindiona, aplicación de los mismos y medicamentos que los contienen